At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
Pemigatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)
In Brief
A Phase 2 clinical trial evaluating Pemigatinib for Cholangiocarcinoma. Completed, enrolled 147 participants across 120 sites in 12 countries.
Detailed Summary
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma
CountriesBelgium, France, Germany, Israel, Italy, Japan, South Korea, Spain, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartJan 2017
Primary CompletionFeb 2022
TodayJul 2026
First PostedOct 5, 2016
Enrollment StartJan 16, 2017
Primary CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.7 years ago
Interventions
Pemigatinibdrug
Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy